MiMedx Group is projected to report Q3 2026 revenue of $68.56 million and break-even earnings per share of $0.00, while the stock currently trades at $3.88 against a $8.40 analyst target. Investors are primarily focused on the stabilization of the Wound Care franchise following significant Medicare reimbursement headwinds that have pressured domestic sales.
Supporting this outlook, recent performance has been characterized by a nearly 40% year-over-year revenue decline, though management highlights continued growth in the Advanced Surgical segment. Additionally, markets are monitoring the regulatory timeline for the Sanara MedTech merger after an FTC "Second Request" introduced uncertainty regarding the deal's year-end closure.